1. Home
  2. SCWO vs IMUX Comparison

SCWO vs IMUX Comparison

Compare SCWO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 374Water Inc.

SCWO

374Water Inc.

N/A

Current Price

$0.23

Market Cap

72.8M

Sector

Utilities

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

N/A

Current Price

$0.59

Market Cap

85.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCWO
IMUX
Founded
2021
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.8M
85.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCWO
IMUX
Price
$0.23
$0.59
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$6.00
AVG Volume (30 Days)
1.2M
1.4M
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,910,340.00
N/A
Revenue This Year
$5,945.19
N/A
Revenue Next Year
$106.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
508.52
N/A
52 Week Low
$0.16
$0.55
52 Week High
$1.09
$1.39

Technical Indicators

Market Signals
Indicator
SCWO
IMUX
Relative Strength Index (RSI) 40.79 38.15
Support Level $0.22 $0.55
Resistance Level $0.27 $0.65
Average True Range (ATR) 0.03 0.04
MACD 0.00 -0.00
Stochastic Oscillator 38.49 22.84

Price Performance

Historical Comparison
SCWO
IMUX

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: